Compass Therapeutics (NASDAQ:CMPX) Stock Rating Upgraded by Leerink Partners

Compass Therapeutics (NASDAQ:CMPX) was upgraded by equities researchers at Leerink Partners from a “market perform” rating to an “outperform” rating in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a $6.00 price target on the stock, up from their previous price target of $4.00. Leerink Partners’ price target would suggest a potential upside of 167.86% from the stock’s previous close.

Several other equities analysts have also issued reports on CMPX. Jefferies Financial Group boosted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. Guggenheim began coverage on Compass Therapeutics in a research note on Monday, February 24th. They issued a “buy” rating and a $12.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. D. Boral Capital reiterated a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday. Finally, Piper Sandler started coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Compass Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $11.63.

Compass Therapeutics Trading Up 17.9 %

Compass Therapeutics stock opened at $2.24 on Wednesday. The firm has a market capitalization of $309.75 million, a P/E ratio of -6.05 and a beta of 1.19. The business has a 50-day moving average of $2.83 and a 200-day moving average of $2.11. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Enavate Sciences GP LLC bought a new stake in Compass Therapeutics in the 4th quarter valued at approximately $11,293,000. Tang Capital Management LLC lifted its position in shares of Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after purchasing an additional 4,087,005 shares in the last quarter. MPM Bioimpact LLC boosted its holdings in Compass Therapeutics by 51.9% during the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after purchasing an additional 2,926,002 shares during the last quarter. SG Americas Securities LLC grew its position in Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after purchasing an additional 356,352 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Compass Therapeutics by 512.5% in the fourth quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company’s stock valued at $395,000 after purchasing an additional 227,864 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.